|
CBX1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.49744669389429E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.91539999999657E-05 |
| Normal-vs-Stage3 |
4.84057238736568E-13 |
| Normal-vs-Stage4 |
1.55431223447522E-15 |
| Stage1-vs-Stage2 |
3.054100E-02 |
| Stage1-vs-Stage3 |
1.768210E-01 |
| Stage1-vs-Stage4 |
4.369200E-04 |
| Stage2-vs-Stage3 |
4.421000E-03 |
| Stage2-vs-Stage4 |
1.622110E-04 |
| Stage3-vs-Stage4 |
7.728000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.870681966755E-13 |
| Normal-vs-AfricanAmerican |
3.68990000000347E-05 |
| Normal-vs-Asian |
2.51430000153263E-08 |
| Caucasian-vs-AfricanAmerican |
2.376200E-01 |
| Caucasian-vs-Asian |
1.843420E-01 |
| AfricanAmerican-vs-Asian |
8.725400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.95032878735901E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
1.033800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.08342240629145E-12 |
| Normal-vs-Age(41-60Yrs) |
2.02060590481778E-14 |
| Normal-vs-Age(61-80Yrs) |
1.65678581964812E-12 |
| Normal-vs-Age(81-100Yrs) |
1.438420E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.388600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.166600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.892400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.722600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.836400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.223000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.982900E-04 |
| Classical-VS-Follicular |
5.456600E-01 |
| Classical-VS-Other |
6.472800E-01 |
| Classical-VS-Normal |
5.00770536149275E-11 |
| Tall-VS-Follicular |
1.904670E-03 |
| Tall-VS-Other |
2.313600E-01 |
| Tall-VS-Normal |
3.73034936274053E-14 |
| Follicular-VS-Other |
6.951200E-01 |
| Follicular-VS-Normal |
2.20429996478089E-09 |
| Other-VS-Normal |
2.473700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.09672296086683E-14 |
| Normal-vs-N1 |
1.13242748511766E-14 |
| N0-vs-N1 |
2.624100E-03 |
|
|
